Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy
Public ClinicalTrials.gov record NCT02345772. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer (NeoHTTP Study)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Hormonal therapy administered before surgery in ER-positive and HER2-positive patients with breast cancer.
Study identification
- NCT ID
- NCT02345772
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 4 participants
Conditions and interventions
Interventions
- fulvestrant 500 mg Drug
- Docetaxel Drug
- Trastuzumab (H, 8mg/kg Drug
- Pertuzumab (P, 840 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2014
- Primary completion
- Oct 31, 2015
- Completion
- Oct 31, 2015
- Last update posted
- Feb 19, 2018
2014 – 2015
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Western Regional Medical Center, Inc. | Goodyear | Arizona | 85338 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated HER2-positive Breast Cancer trials
Other public records listing HER2-positive Breast Cancer. Sorted by last update posted; newest first. Not a recommendation.
- NCT07413939: RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Recruiting
- NCT03747120: Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP] Active, not recruiting
- NCT05115474: Study of Screening Brain MRIs in Stage IV Breast Cancer Recruiting
- NCT07053085: A Study of Surgery and Radiotherapy in People With Breast Cancer Recruiting
- NCT05809752: A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) Active, not recruiting
- NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02345772, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 19, 2018 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02345772 live on ClinicalTrials.gov.